<p>(Upper panel) Cumulative incidence of discontinuation during the follow-up period. The unadjusted cumulative incidence of discontinuation was lower among patients initiated on apixaban compared to patients inititated on other oral anticoagulants. (Lower panel) The number of patients at risk for discontinuation at varying points during the follow-up.</p
Background and Aim Warfarin treatment discontinuation is significant among patients with atrial fibr...
Medication non-adherence can result in poor health outcomes. Understanding differences in adherence ...
BACKGROUND: Oral anticoagulation (OAC) in atrial fibrillation (AF) reduces the risk of stroke/system...
<div><p>Discontinuation of oral anticoagulants may expose non-valvular atrial fibrillation (NVAF) pa...
Discontinuation of oral anticoagulants may expose non-valvular atrial fibrillation (NVAF) patients t...
Aims: We sought to investigate the reasons for, and rates of, novel oral anticoagulant (DOAC) therap...
BACKGROUND AND AIM:Interruption of anticoagulant treatment with warfarin or non-vitamin K antagonist...
AIMS: Real-world data on treatment persistence, safety and effectiveness of non-Vitamin K antagonist...
<p>Proportion of patients who permanently discontinued all therapy due to adverse events after strat...
AIMS: Real-world data on treatment persistence, safety and effectiveness of non-Vitamin K antagonist...
ObjectivesThe purpose of this study was to understand the possible risk of discontinuation in the co...
Unadjusted annual cumulative incidence of bleeding among non-valvular atrial fibrillation (nvaf) pat...
Background—Although warfarin is widely recommended to prevent atrial fibrillation-related thromboemb...
Background/Aims Efforts to reduce stroke in patients with atrial fibrillation (AF) have focused on i...
BACKGROUND: Guidelines recommend long-term oral anticoagulation therapy for stroke prevention in pat...
Background and Aim Warfarin treatment discontinuation is significant among patients with atrial fibr...
Medication non-adherence can result in poor health outcomes. Understanding differences in adherence ...
BACKGROUND: Oral anticoagulation (OAC) in atrial fibrillation (AF) reduces the risk of stroke/system...
<div><p>Discontinuation of oral anticoagulants may expose non-valvular atrial fibrillation (NVAF) pa...
Discontinuation of oral anticoagulants may expose non-valvular atrial fibrillation (NVAF) patients t...
Aims: We sought to investigate the reasons for, and rates of, novel oral anticoagulant (DOAC) therap...
BACKGROUND AND AIM:Interruption of anticoagulant treatment with warfarin or non-vitamin K antagonist...
AIMS: Real-world data on treatment persistence, safety and effectiveness of non-Vitamin K antagonist...
<p>Proportion of patients who permanently discontinued all therapy due to adverse events after strat...
AIMS: Real-world data on treatment persistence, safety and effectiveness of non-Vitamin K antagonist...
ObjectivesThe purpose of this study was to understand the possible risk of discontinuation in the co...
Unadjusted annual cumulative incidence of bleeding among non-valvular atrial fibrillation (nvaf) pat...
Background—Although warfarin is widely recommended to prevent atrial fibrillation-related thromboemb...
Background/Aims Efforts to reduce stroke in patients with atrial fibrillation (AF) have focused on i...
BACKGROUND: Guidelines recommend long-term oral anticoagulation therapy for stroke prevention in pat...
Background and Aim Warfarin treatment discontinuation is significant among patients with atrial fibr...
Medication non-adherence can result in poor health outcomes. Understanding differences in adherence ...
BACKGROUND: Oral anticoagulation (OAC) in atrial fibrillation (AF) reduces the risk of stroke/system...